CONFERENCE PROCEEDINGS
Advanced Search
Home > Proceedings > Volume PC12826 > Article
Presentation
13 March 2024 A triple-blinded, sham controlled study of transcranial photobiomodulation for Parkinson’s disease symptoms
Ann Liebert, Claire McGee, Brian Bicknell, Vincent Pang, Vivian Isaac, Craig McLachlan, Hosen Kiat, Geoffrey Herkes
Author Affiliations +
Proceedings Volume PC12826, Mechanisms of Photobiomodulation Therapy XVIII; PC1282602 (2024) https://doi.org/10.1117/12.3008951
Event: SPIE BiOS, 2024, San Francisco, California, United States
Abstract
A number of studies have suggested that PBM can have positive effects on the symptoms of Parkinson’s disease. The objective of this study was to determine the safety and efficacy of transcranial photobiomodulation (tPBM) for Parkinson’s disease symptoms, including motor symptoms, as measured by UPDRS, and sense of smell and patient reported outcomes. A 20+20 double-blind, randomised, sham controlled trial was conducted over 24 weeks, with Group 1 having sham helmet for 12 weeks and then active helmet for 12 weeks and Group 2 having active helmet for 12 weeks and then no treatment for 12 weeks. The clinical trial was conducted entirely remotely during the COVID-19 restrictions. Despite a large placebo effect, the treatment was found to be both safe and effective, with a clinically and statistically significant reduction in UPDRS scores. There were also improvements in some participants sense of smell and quality of life.
Conference Presentation
© (2024) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Citation Download Citation
Ann Liebert, Claire McGee, Brian Bicknell, Vincent Pang, Vivian Isaac, Craig McLachlan, Hosen Kiat, and Geoffrey Herkes "A triple-blinded, sham controlled study of transcranial photobiomodulation for Parkinson’s disease symptoms", Proc. SPIE PC12826, Mechanisms of Photobiomodulation Therapy XVIII, PC1282602 (13 March 2024); https://doi.org/10.1117/12.3008951
ACCESS THE FULL ARTICLE
ORGANIZATIONAL
Sign in with credentials provided by your organization.
INSTITUTIONAL
Select your institution to access the SPIE Digital Library.
SELECT YOUR INSTITUTION
PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
PERSONAL SIGN IN
No SPIE Account? Create one
PURCHASE THIS CONTENT
SUBSCRIBE TO DIGITAL LIBRARY
50 downloads per 1-year subscription
Members: $195
Non-members: $335 ADD TO CART
25 downloads per 1 - year subscription
Members: $145
Non-members: $250 ADD TO CART
PURCHASE SINGLE ARTICLE
Includes PDF, HTML & Video, when available
Members: $17.00
Non-members: $21.00 ADD TO CART
PROCEEDINGS
 PRESENTATION
WATCH
PRESENTATION SAVE TO MY LIBRARY
GET CITATION
Advertisement
Advertisement
KEYWORDS
Parkinson disease
Clinical trials
Safety
Animals
COVID 19
Video
RELATED CONTENT
Subscribe to Digital Library
Receive Erratum Email Alert
Back to Top